{"id":"olanzapine-fluoxetine-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Metabolic syndrome"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake. The combination targets both dopaminergic and serotonergic pathways to address psychotic and depressive symptoms simultaneously.","oneSentence":"Olanzapine blocks dopamine and serotonin receptors while fluoxetine inhibits serotonin reuptake, together providing antipsychotic and antidepressant effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:03.977Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar I disorder depression"},{"name":"Treatment-resistant depression with psychotic features"}]},"trialDetails":[{"nctId":"NCT04876521","phase":"PHASE4","title":"Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2019-10-14","conditions":"Post-Schizophrenic Depression","enrollment":60},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT00339079","phase":"PHASE1, PHASE2","title":"Treatment of Hypochondriasis With CBT and/or SSRI","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-06","conditions":"Hypochondriasis","enrollment":195},{"nctId":"NCT00489593","phase":"PHASE1","title":"Olanzapine in Patients With Advanced Cancer and Weight Loss","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-10","conditions":"Advanced Cancer, Weight Loss","enrollment":57},{"nctId":"NCT00958568","phase":"PHASE3","title":"A Study in Relapse Prevention of Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Treatment Resistant Depression","enrollment":892},{"nctId":"NCT00000373","phase":"PHASE4","title":"Treatment of Obsessive-Compulsive Disorder","status":"COMPLETED","sponsor":"University of Florida","startDate":"1992-09","conditions":"Obsessive-Compulsive Disorder","enrollment":74},{"nctId":"NCT00844857","phase":"PHASE4","title":"A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":291},{"nctId":"NCT00188942","phase":"PHASE4","title":"A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2005-02","conditions":"Major Depressive Disorder","enrollment":42},{"nctId":"NCT00512291","phase":"NA","title":"Subcutaneous Olanzapine for Hyperactive or Mixed Delirium","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-06","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT00485810","phase":"PHASE1, PHASE2","title":"Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-06","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT00485901","phase":"PHASE3","title":"Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-07","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT00485498","phase":"PHASE4","title":"Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-04","conditions":"Schizophrenia","enrollment":122},{"nctId":"NCT00486005","phase":"PHASE4","title":"Weight Gain Management in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-02","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT00485680","phase":"PHASE3","title":"Olanzapine Versus Comparator in the Treatment of Bipolar Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-12","conditions":"Bipolar Disorder","enrollment":140},{"nctId":"NCT00485771","phase":"PHASE4","title":"Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-11","conditions":"Bipolar Disorder","enrollment":403},{"nctId":"NCT00485823","phase":"PHASE4","title":"Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-12","conditions":"Schizophrenic Disorders","enrollment":48},{"nctId":"NCT00035321","phase":"PHASE3","title":"The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-04","conditions":"Major Depressive Disorder","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":102,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oleanz Fort","Oleanz Plus"],"phase":"marketed","status":"active","brandName":"Olanzapine-Fluoxetine Combination","genericName":"Olanzapine-Fluoxetine Combination","companyName":"All India Institute of Medical Sciences, Bhubaneswar","companyId":"all-india-institute-of-medical-sciences-bhubaneswar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine blocks dopamine and serotonin receptors while fluoxetine inhibits serotonin reuptake, together providing antipsychotic and antidepressant effects. Used for Bipolar I disorder depression, Treatment-resistant depression with psychotic features.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}